We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops therapeutics that address important unmet medical needs in neurotology, rhinology, allergy, and CNS disorders. It has two projects in clinical development: Keyzilen for the treatment of acute inner ear tinn... Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops therapeutics that address important unmet medical needs in neurotology, rhinology, allergy, and CNS disorders. It has two projects in clinical development: Keyzilen for the treatment of acute inner ear tinnitus and Sonsuvi for the treatment of acute inner ear hearing loss. Its other product candidates are AM-125, AM-201, and AM-301. Show more
Hamilton, Bermuda, July 15, 2021 β Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
Bentrioβ’ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs...
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhoreβ’ platformCompany to launch development program under project code AM-401 with aim of IND...
Hamilton, Bermuda, June 28, 2021 β Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive...
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasirβs innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of...
Hamilton, Bermuda, June 1, 2021 β Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Hamilton, Bermuda, May 28, 2021 β Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 β Auris Medical...
Hamilton, Bermuda, May 14, 2021 β Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions